
Background Acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19) carried high mortality before vaccines became available, and options for patients who deteriorate despite corticosteroids and antivirals are limited. Umbilical cord-derived mesenchymal stromal cells (UC-MSCs) have anti-inflammatory and tissue-reparative properties. HLC-001 is a cryopreserved, serum-free manufactured allogeneic UC-MSC product. We report the first patients treated with HLC-001 for COVID-19 ARDS. Case report In an open-label, single-arm, single-centre phase 1 trial using a 3 + 3 design, three unvaccinated Japanese men aged 65, 79 and 81 years with COVID-19 ARDS by the Berlin definition that had not improved on standard care received HLC-001 2.0 × 106 cells/kg intravenously twice weekly for two cycles (four infusions). None was intubated at enrolment; all received remdesivir and systemic corticosteroids. The primary endpoint was dose-limiting toxicity (DLT) up to 28 days after the last infusion. Results No DLT occurred and the starting dose was considered tolerable. Eighteen adverse events were recorded in the three patients; none was attributed to HLC-001 by the investigator or the Data Safety Monitoring Board, and no grade 4 or 5 event, serious adverse event or death occurred. Two grade 3 events, alanine aminotransferase elevation and creatine kinase elevation, were attributed to concomitant medication (corticosteroid, with a possible contribution of trimethoprim/sulfamethoxazole to the alanine aminotransferase elevation) and resolved. No patient required mechanical ventilation, all were weaned from supplemental oxygen, and SARS-CoV-2 PCR was negative at the final on-study assessment in all three. Conclusion HLC-001 at 2.0 × 106 cells/kg was tolerated in three non-intubated patients with COVID-19 ARDS. An uncontrolled series of this size cannot assess efficacy, and the observed clinical course is hypothesis-generating only. This study was registered with the Japan Registry of Clinical Trials (jRCT1080225369).
Background: Malaria is an important imported infection in the United Kingdom, while infrequent exposure in low-incidence settings may increase the risk of delayed diagnosis and treatment. We evaluated the timeliness of malaria diagnosis and antimalarial treatment, and adherence to treatment guidance, within NHS Lothian. Methods: We conducted a retrospective clinical audit of all patients treated for malaria within NHS Lothian between January 2023 and April 2025. Data were obtained from electronic prescribing (HEPMA), clinical records (TRAKCare), and laboratory communication logs (APEX). Time intervals from presentation through antimalarial administration were analysed. Apparent delays identified from electronic timestamps were reclassified following detailed case-note review. Results: Forty-three patients were included. Malaria testing was performed at first presentation in 81% of cases and all patients were reviewed by an infectious diseases specialist. Nine patients (21%) met criteria for severe malaria and 12 (28%) had an indication for intravenous artesunate. Appropriate antimalarial therapy was delivered in 38/43 (88%). Four patients (9%) had a missed diagnosis on an earlier clinical presentation. Electronic timestamp analysis identified apparent treatment delays in 19/43 (44%); after case-note review, nine confirmed delays remained, or 11 including two obstetric cases with incomplete documentation. Antimalarial stock unavailability was the most frequent contributor. Five patients (12%) received therapy not fully concordant with local guidance. Conclusion: Malaria management within NHS Lothian was generally timely and guideline-concordant. Confirmed delays were predominantly related to system-level factors, particularly medication availability and prescribing logistics. Electronic timestamp analysis substantially overestimated delays when used without case-note review. A point-of-care malaria algorithm, standardised emergency antimalarial stock arrangements, and targeted obstetric education have been implemented, with re-audit planned.